FDA approves first biosimilar for the treatment of cancer - FDA Press Releases

The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the treatment of cancer.

from Food and Drug Administration--Press Releases http://ift.tt/2xnnmIf
via IFTTT